Polymerase η mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 1039-1045

  Ceppi, Paolo ^a   Novello, Silvia ^a   Cambieri, Alberto ^a   Longo, Marina ^a   Monica, Valentina ^a   Lo Iacono, Marco ^a   Giaj Levra, Matteo ^a   Saviozzi, Silvia ^a   Volante, Marco ^a   Papotti, Mauro ^a   Scagliotti, Giorgio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA DIRECTED DNA POLYMERASE ETA; FORMALDEHYDE; GEMCITABINE; MESSENGER RNA; PACLITAXEL; PARAFFIN; PEMETREXED;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 61349137712     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1227     Document Type: Article

References (29)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43 -66.
3. Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311: 899-909.
4. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis- diammine-(1, 1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res1986;46:1972 -9.
5. Lawley PD, Phillips DH. DNA adducts from chemo-therapeutic agents. Mutat Res1996;355:13 -40.
6. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev1998;24:331 -44.
7. 6- ethenodeoxyadenosine. J Biol Chem 2001;276:18717 -21.
8. Chen YW, Cleaver JE, Hanaoka F, Chang CF, Chou KM. A novel role of DNA polymerase η in modulating cellular sensitivity to chemotherapeutic agents. Mol Cancer Res 2006;4:257 -65.
9. Masutani C, Kusumoto R, Yamada A, et al. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase η. Nature 1999;399:700-4.
10. Haracska L, YuSL, Johnson RE, Prakash L, Prakash S. Efficient and accurate replication in the presence of 7, 8-dihydro-8-oxoguanine by DNA polymerase η. Nat Genet 2000;25:458-61.
11. Zhang Y, Yuan F, Wu X, et al. Error-prone lesion bypass by human DNA polymerase η. Nucleic Acids Res 2000;28:4717 -24.
12. Masutani C, Araki M, Yamada A, et al. Xeroderma pigmentosum variant (XP-V) correcting protein from HeLa cells has a thymine dimer bypass DNA polymerase activity. EMBO J 1999;18:3491 -501.
13. Hubscher U, Maga G, Spadari S. Eukaryotic DNA polymerases. Annu Rev Biochem 2002;71:133-63.
14. Johnson RE, Prakash S, Prakash L. Efficient bypass of a thymine-thymine dimer by yeast DNA polymerase, PoIη. Science 1999;283:1001 -4.
15. Albertella MR, Green CM, Lehmann AR, O'Connor MJ. A role for polymerase η in the cellular tolerance to cisplatin-induced damage. Cancer Res 2005;65:9799-806.
16. Alt A, Lammens K, Chiocchini C, et al. Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase η. Science 2007;318:967 -70.
17. Vaisman A, Masutani C, Hanaoka F, Chaney SG. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase η. Biochemistry 2000;39:4575 -80.
18. Pan Q, Fang Y, Xu Y, Zhang K, Hu X. Down-regulation of DNA polymerases κ, ηι, and ζ in human lung, stomach, and colorectal cancers. Cancer Lett 2005;217:139 -47.
19. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-25.
20. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000;4:135-42.
21. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589 -96.
22. Rapa I, Ceppi P, Bollito E, et al. Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Mod Pathol 2008;21:700-7.
23. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94:1091 -9.
24. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004;13:2443 -9.
25. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004;10:1318-25.
26. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin- based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
27. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-83.
28. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007;2:e1129.
29. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8.